Quantum BioPharma Ltd. Supports Unbuzzd's $5 Million Fundraising Effort
Quantum BioPharma Ltd. backs Unbuzzd Wellness Inc. in a $5 million Regulation D offering, aiming to expand the reach of its hangover-reducing beverage and paving the way for a future IPO.
Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company specializing in innovative treatments for neurodegenerative and metabolic disorders, has announced its support for Unbuzzd Wellness Inc.'s $5 million fundraising initiative through a Regulation D 506(c) offering. Unbuzzd, known for its beverage unbuzzd(TM) designed to accelerate alcohol metabolism and alleviate hangover symptoms, plans to utilize the raised funds to broaden its distribution channels, including direct-to-consumer, retail, and distributor networks.
Under the leadership of CEO John Duffy, a former Coca-Cola executive, and with strategic advice from Gerry David, the ex-CEO of Celsius Holdings, Unbuzzd views this fundraising as a critical step towards achieving its goal of an initial public offering (IPO). Quantum BioPharma's involvement underscores its commitment to fostering biotech innovation and its strategic investment in Unbuzzd, retaining a significant ownership stake and future royalties from sales of unbuzzd(TM).
This development highlights the growing interest in functional beverages that address alcohol-related discomfort, a niche yet expanding market segment. Quantum BioPharma's backing of Unbuzzd not only signifies confidence in the product's potential but also reflects the company's broader strategy to invest in groundbreaking health and wellness solutions. For more details on Quantum BioPharma's initiatives, visit https://ibn.fm/QNTM.